What semaglutide clinical trials actually show about weight loss

You've read the headlines, here's what the trial numbers actually mean

The 15% average weight loss quoted from STEP 1 is a mean across nearly 2,000 participants. Some lost considerably more; others lost less. Trials report averages because that is statistically honest, not because everyone lands at the same number. The participants were adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure or high cholesterol. They received structured lifestyle support throughout, which is important context when you see the headline figure.

The trial lasted 68 weeks. At the end, participants on placebo who also received lifestyle support lost an average of around 2.4%, the lifestyle component alone, without the medicine. That gap is why researchers and clinicians take semaglutide seriously as a treatment rather than a supplement to willpower. The NHS medicines page for semaglutide summarises the mechanism and evidence in plain language if you want a thorough grounding before any consultation.

One practical thing the trials confirmed: most of the gastrointestinal side effects (nausea, loose stools, reflux) were front-loaded. They peaked in the early weeks of treatment or after a dose increase, then settled for most people. Knowing that rhythm helps. It does not mean every patient experiences them, and it does not mean they are trivial when they occur; it means they are manageable with the right clinical support.

The 7.2mg dose: what a newer trial added

For a long time, 2.4mg weekly was the ceiling for semaglutide in weight management. That changed when the MHRA approved a higher 7.2mg maintenance dose in January 2026, with a dedicated single-dose pen approved on 14 April 2026. Trial data for the 7.2mg dose reported average weight loss of around 20.7% over 72 weeks, a meaningful step up from the 2.4mg results and one that narrows the gap with tirzepatide seen in the SURMOUNT-5 head-to-head study.

The 7.2mg licence is specific to adults with a BMI of 30 or above. It does not extend to the cardiovascular indication. The titration schedule still starts at 0.25mg and steps up roughly every four weeks; no one begins at 7.2mg. What the higher ceiling means clinically is that patients who tolerate the medicine well and have not reached their weight-management goal at 2.4mg now have an additional option to explore with their prescriber, rather than a hard stop.

If you want to read the full trial data behind the 7.2mg approval, the Wegovy clinical trial breakdown covers the key studies in more detail, including how the higher dose compares across different participant groups.

Who the trial data applies to, and where it gets complicated

Trial eligibility and clinical eligibility are not the same thing. STEP 1 excluded people with type 2 diabetes, which is why a separate STEP programme exists for that population. NICE's recommendation for semaglutide (Wegovy) under TA875 applies to adults with at least one weight-related comorbidity and a BMI of 35 or above for NHS access, within a specialist weight management service and for a maximum of two years. The private licensed threshold is lower: BMI 30 or above, or 27 with a qualifying condition.

Reduced BMI thresholds apply for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds under UK guidance. That adjustment reflects differences in metabolic risk at equivalent BMI values and is built into the NICE recommendations.

For a full picture of how the NHS is rolling out semaglutide access, the NHS semaglutide weight loss page covers eligibility phases and what the waitlists currently look like. The short version: NHS access is real but tightly phased. Many people who would benefit clinically do not yet meet the current NHS criteria, or face long waits at specialist services.

From trial evidence to a private prescription: what the process looks like

Clinical trials establish that a medicine works on average in a defined population. A prescriber's job is to work out whether you specifically are a reasonable candidate, checking your medical history, current medicines, BMI, and any conditions that might make treatment unsuitable or require extra care. That assessment cannot be skipped, and any route that offers semaglutide without one is not a safe route.

At a regulated pharmacy like ours, that process starts with a free online consultation. A GPhC-registered Independent Prescriber reads your answers the same day, a real clinician, not an automated filter. If treatment is clinically appropriate, your prescription is issued and the order dispatched the same day for free next-working-day delivery via DPD, in plain packaging. If you are curious about the clinical trial evidence behind semaglutide and what it means for your own situation, that detail can help you go into a consultation better prepared. If you want to understand what Wegovy costs through a private clinic, the Wegovy price guide walks through what drives the variation and what a legitimate price should include.

The trial data is compelling. Whether it applies to your situation is the conversation worth having. Speak to our prescribers when you're ready, and if the commercial side of the medicine interests you, our page on how to buy shares in Wegovy explains what that actually involves.